Qiagen NV (QGEN) - Market Cap to Net Income Ratio

Symbol and logo of brand Qiagen Group (QGEN)

The P/E ratio history demonstrates the impact of Qiagen N.V. (QGEN) innovations in DNA sample preparation essential for precision medicine. The current ratio stands at 27.10, supported by strong pricing power resulting from the complexity of recertifying laboratory protocols. The stability of the share price is ensured by a robotic analysis ecosystem, where dependence on specific cartridges makes switching providers economically unfeasible for clients.

QGEN Qiagen NV: Price to Earnings Ratio in the range 07/04/2022 - 11/16/2026

Analytical breakdowns for Qiagen N.V.

- price and consensus price forecast:
- market capitalization indicators:
General company analysis:Qiagen N.V.
Flagship merchandise of qiagen.com

The P/E ratio determines the market value of a business relative to its annual net income, reflecting current investor expectations. Analyzing the P/E chart for Qiagen N.V. (QGEN) helps identify the risk of overpayment or creates opportunities for a favorable entry into the asset. This indicator's trend confirms the fundamental stability of Qiagen N.V. (QGEN) due to its leadership in the DNA diagnostics segment. High regulatory barriers make the company an indispensable supplier, stabilizing its investment attractiveness.

Competing companies

tempus.com - Market Cap to Net Income|P/E Multiple IONS|Price to Earnings Ratio RGEN (Repligen Corp.)|Avidity - Price to Earnings Ratio|CRSP (crisprtx.com) - Market Cap to Net Income|WGS: Price to Earnings Ratio|Market Cap to Net Income Ratio Ultragenyx (RARE)|BEAM: P/E Multiple|Sarepta Therapeutics, Inc. (SRPT) - P/E Multiple|TWST (twistbioscience.com) - P/E Multiple|10x Genomics, Inc. (TXG) - Business Payback Period|Price to Earnings Ratio NTLA (Intellia Therapeutics, Inc.)|STOK - Market Cap to Earnings|Price to Earnings Ratio biolifesolutions.com BLFS|Business Payback Period Wave Life Sciences Corp (WVE)|MAZE - Price to Earnings Ratio|Company Value to Net Income SION (Sionna Therapeutics Inc)|PRME: P/E Multiple|Taysha - Company Value to Net Income|Price to Earnings Ratio uniQure NV|Price to Earnings Multiple MGTX (MeiraGTx PLC)|Price to Earnings Ratio RGNX (regenxbio.com)|Solid Biosciences Inc. - Price to Earnings Multiple|Price to Earnings Ratio Ocugen Corp OCGN|Pacific Biosciences of California, Inc. (PACB) - Market Cap to Earnings|BNTC - Price to Earnings Ratio|Design Pharma - Market Price to Net Income Ratio|RCKT (Rocket Pharmaceuticals Inc) - Price to Earnings Ratio|4D Molecular Therapeutics (FDMT) - P/E Multiple|Price to Earnings Ratio Lexeo Therapeutics, Inc.|Market Cap to Earnings Korro Bio, Inc. KRRO|P/E Multiple EDIT|Business Payback Period Silence Therapeutics Corp|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio